Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high‐grade serous ovarian cancer

2020 ◽  
Vol 147 (2) ◽  
pp. 565-574 ◽  
Author(s):  
Giuseppe Benvenuto ◽  
Paola Todeschini ◽  
Lara Paracchini ◽  
Enrica Calura ◽  
Robert Fruscio ◽  
...  
PLoS ONE ◽  
2009 ◽  
Vol 4 (7) ◽  
pp. e6412 ◽  
Author(s):  
Katy Milne ◽  
Martin Köbel ◽  
Steven E. Kalloger ◽  
Rebecca O. Barnes ◽  
Dongxia Gao ◽  
...  

2019 ◽  
Vol 215 (6) ◽  
pp. 152369
Author(s):  
Dominique Trudel ◽  
Luminita-Mihaela Avarvarei ◽  
Michèle Orain ◽  
Stéphane Turcotte ◽  
Marie Plante ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Tomer Feigenberg ◽  
Blaise Clarke ◽  
Carl Virtanen ◽  
Anna Plotkin ◽  
Michelle Letarte ◽  
...  

Epithelial ovarian cancer consists of multiple histotypes differing in etiology and clinical course. The most prevalent histotype is high-grade serous ovarian cancer (HGSOC), which often presents at an advanced stage frequently accompanied with high-volume ascites. While some studies suggest that ascites is associated with poor clinical outcome, most reports have not differentiated between histological subtypes or tumor grade. We compared genome-wide gene expression profiles from a discovery cohort of ten patients diagnosed with stages III-IV HGSOC with high-volume ascites and nine patients with low-volume ascites. An upregulation of immune response genes was detected in tumors from patients presenting with low-volume ascites relative to those with high-volume ascites. Immunohistochemical studies performed on tissue microarrays confirmed higher expression of proteins encoded by immune response genes and increased tumorinfiltrating cells in tumors associated with low-volume ascites. Comparison of 149 advanced-stage HGSOC cases with differential ascites volume at time of primary surgery indicated low-volume ascites correlated with better surgical outcome and longer overall survival. These findings suggest that advanced stage HGSOC presenting with low-volume ascites reflects a unique subgroup of HGSOC, which is associated with upregulation of immune related genes, more abundant tumor infiltrating cells and better clinical outcomes.


2020 ◽  
Author(s):  
Shahan Mamoor

Ovarian cancer is the most lethal gynecologic cancer (1). We sought to identify genes associated with high-grade serous ovarian cancer (HGSC) by comparing global gene expression profiles of normal ovary with that of primary tumors from women diagnosed with HGSC using published microarray data (2,3). We previously identified forkhead box L2 (4), (FOXL2) as among the genes whose expression was most different in HGSC ovarian tumors when compared to the ovary. Here, we find that potential FOXL2 transcriptional target (5,6) odd-skipped related gene OSR2 (7) is differentially expressed in high-grade serous ovarian cancer, and could be observed in independent tumor microarray data (2,3). These data reveal perturbed expression of a target gene of a key transcription factor and specifier of ovarian cell fate in high-grade serous ovarian cancers.


2020 ◽  
Author(s):  
Shahan Mamoor

High-grade serous ovarian cancer (HGSC) is the most common type of the most lethal gynecologic malignancy (1). To identify genes whose expression was associated with survival outcomes in HGSC, we used published data from patients enrolled in the ICON7 trial to compare the global gene expression profiles of primary HGSC tumors from women with the best and worst progression-free survival (PFS) (2). We found that the Frizzled class 7 (Fzd7) receptor was among the genes most differentially expressed in HGSC tumors when comparing tumor transcriptomes based on superior or inferior PFS. In two independent datasets, Fzd7 was among the genes most differentially expressed in HGSC tumors when comparing primary tumor to the normal ovary (3, 4). Wnt pathway signaling through Fzd7 may be relevant to the biology of high-grade serous ovarian cancers.


2020 ◽  
Author(s):  
Shahan Mamoor

Ovarian cancer is the most lethal gynecologic cancer (1). We sought to identify genes associated with high-grade serous ovarian cancer (HGSC) by comparing global gene expression profiles of normal ovary with that of primary tumors from women diagnosed with HGSC using published microarray data (2, 3). Here, we report significant differential sense and anti-sense transcription at the PGM locus in high-grade serous ovarian tumors.


2020 ◽  
Author(s):  
Shahan Mamoor

Ovarian cancer is the most lethal gynecologic cancer (1). We sought to identify genes associated with enhanced survival in high-grade serous ovarian cancer (HGSC) by comparing global gene expression profiles of tumors from women diagnosed with HGSC with the best and worst progression-free survival (2). We found significant differential expression of the gene encoding the cytokine interleukin-16 (IL-16) when comparing tumor transcriptomes based on progression-free survival. IL-16 was expressed at significantly lower levels in high-grade serous ovarian tumors of women with the longest progression-free survival.


2020 ◽  
Author(s):  
Shahan Mamoor

Ovarian cancer is the most lethal gynecologic cancer (1). We sought to identify genes associated with enhanced survival in high-grade serous ovarian cancer (HGSC) by comparing global gene expression profiles of tumors from women diagnosed with HGSC with the best and worst progression-free survival (2). We found significant differential expression of the gene encoding the receptor antagonist for the cytokine interleukin-1 (IL-1) (IL-1RN) when comparing tumor transcriptomes based on progression-free survival. IL-1RN was expressed at significantly lower levels in high-grade serous ovarian tumors of women with the longest progression-free survival.


Sign in / Sign up

Export Citation Format

Share Document